The Consistency Breakthrough
in EV Therapeutics
FT-01: A scalable platform for reliable, clinical-grade extracellular vesicles
Solving the Critical Bottleneck
Traditional EV production has relied on variable primary donor cells, creating an inconsistent source that yields inconsistent EV products. This fundamental challenge has prevented EV therapies from reaching their clinical and commercial potential.
FT-01 represents a paradigm shift: our proprietary, immortalised mesenchymal stem cell line provides an inexhaustible supply of bioactive EVs with consistent characteristics. This breakthrough combines the therapeutic benefits of cell-based treatments with pharmaceutical-grade reproducibility and superior safety profiles.
Platform Technology Deep Dive
FT-01 was developed through decades of expertise in mesenchymal stem cells and extracellular vesicles. Our research journey identified and developed the ideal MSC clone through rigorous scientific evaluation, resulting in unique advantages that set our platform apart.
Scientific Foundation
Every FT-01 cell shares identical genetic characteristics, ensuring that EVs produced across different batches maintain consistent therapeutic properties. This eliminates the donor-to-donor variability that has plagued traditional EV production methods.
Immortalised Cell Line Properties
Unlike primary cells that age and change over time, FT-01 maintains stable characteristics through extensive passaging, providing an inexhaustible source for large-scale production.
Comprehensive EV Characterisation
Our comprehensive characterisation includes extensive biophysical analysis and cargo profiling, ensuring that FT-01 EVs maintain consistent therapeutic properties including growth factors, cytokines, and regulatory molecules that drive tissue repair and immune modulation.
Clonal Cell Line Technology
Manufacturing Excellence
Breakthrough Scalability
FT-01 has demonstrated remarkable scalability, achieving an 84% reduction in the cost of goods while maintaining product quality. This breakthrough makes clinical-grade EV production economically viable for widespread therapeutic application.
-
Scalable from pilot to commercial production volumes
Consistent yield and quality across production runs
Standard bioreactor compatibility for established manufacturing infrastructure
Reduced raw material costs compared to donor-dependent processes
-
Our platform incorporates GMP-ready processes and quality controls, ensuring regulatory compliance and product consistency. This includes comprehensive characterisation methods, stability protocols, and release testing procedures.
Therapeutic Applications
Versatile Platform for Diverse Applications
FT-01 has demonstrated remarkable scalability, achieving an 84% reduction in the cost of goods while maintaining product quality. This breakthrough makes clinical-grade EV production economically viable for widespread therapeutic application.
-
Unmodified FT-01 EVs harness the natural therapeutic properties of mesenchymal stem cells, offering applications in:
Autoimmune and inflammatory conditions
Tissue regeneration and wound healing
Neurodegenerative diseases
Cardiovascular disorders
-
FT-01 EVs can be engineered with tissue-specific targeting capabilities, enabling precise delivery to:
Tumor microenvironments for oncology applications
Central nervous system for neurological disorders
Specific inflammatory sites for localised treatment
-
Our platform enables loading of FT-01 EVs with bespoke therapeutic cargo:
RNA molecules for gene regulation
Therapeutic proteins for targeted biological activity
Small molecule drugs for targeted delivery
Combination therapies for complex multi-pathway diseases
Partnership and Licensing
Accelerating EV Innovation Through Collaboration
FT-01 offers partners a complete solution for EV therapeutic development, eliminating the years typically required to establish consistent production capabilities. Our platform reduces development timelines while significantly lowering manufacturing and regulatory risk.
-
Platform Licensing: Complete access to FT-01 technology for specific therapeutic applications
Joint Development: Collaborative research programs in areas of mutual interest
Manufacturing Services: Production of GMP-grade EVs using our established platform
Technical Support: Knowledge transfer and ongoing scientific collaboration
-
Our strong alignment with key opinion leaders including Versus Arthritis, University of York, and world-class advisory board members supports the scientific credibility and commercial potential of our platform.